Pfizer Signs Academic Collaboration Pact With Peking University To Support Translational R&D Center In Shenzhen
SHANGHAI - After unveiling a plan to build a research and development center in Wuhan last week, Pfizer announced it inked an agreement with Peking University Dec. 1 to fund the university's research projects and to build a translational research and drug discovery center in PKU's Graduate School in Shenzhen, a Chinese city that borders the former British enclave of Hong Kong
More from Archive
More from Scrip
The German group could pay $3.5bn to get hold of the US firm and its two approved products.
Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.
Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.